1928 zT2
Alternative Names: 1928z-T2Latest Information Update: 10 Feb 2024
Price :
$50 *
At a glance
- Originator Wellington Zhaotai Therapies
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 09 Feb 2024 1928 zT2 is available for licensing as of 09 Feb 2024. https://www.wellingtonzhaotai.com/business-development
- 09 Feb 2024 Phase-I clinical trials in Lymphoma at Unknown location (Parenteral) (Wellington Zhaotai Therapies pipeline, February 2024)
- 09 Feb 2024 Phase-I clinical trials in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma at Unknown location (Parenteral) (Wellington Zhaotai Therapies pipeline, February 2024)